Bayer’s Post

Global Cell and Gene Therapy CDMO Market Report, 2019-2023 and 2024-2029 - Rise of Biologics Spurs Investments in Biomanufacturing Facilities by CDMOs: DUBLIN, Jan. 9, 2024 /PRNewswire/ -- The "Global Cell and Gene Therapy CDMO Market: Analysis By Type, Application, Indication, By Region, By Country: Market Insights and Forecast" report has been added to ResearchAndMarkets.com's offering. The Global Cell and Gene Therapy CDMO market...

Precision's Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series. "Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types." Read the article here (subscription required): https://hubs.ly/Q02jhKP30 #precisionmedicine #biopharma #clinicaltrials

Specialized CGT therapies require distinct manufacturing capabilities, so we advise all our clients to choose their consultants and manufacturing partners carefully.  In what ways will increased efficiency boost your efforts to bring new assets to market? #processdevelopment #drugdevelopment #productdevelopment

New promising option in #HF for the next future

Potency Assurance for Cellular and Gene Therapy Products "A potency assurance strategy is a multifaceted approach that reduces risks to the potency of a product through manufacturing process design, manufacturing process control, material control, in-process testing, and potency lot release assays. The goal of a potency assurance strategy is to ensure that every lot of a product released will have the specific ability or capacity to achieve the intended therapeutic effect." #FDA #celltherapy #cellandgenetherapy #manufacturing

+++ Pipeline #News +++ Fast Track Designation for Heart Failure Gene Therapy Asklepios BioPharmaceutical, Inc. (AskBio)'s gene therapy program for congestive heart failure has been granted U.S. FDA Fast Track Designation, emphasizing the need to rapidly advance new therapeutic modalities such as gene therapy for people living with congestive heart failure. Learn more: https://lnkd.in/ekY-krjA #TeamBayer

Check out the July issue of Pharmaceutical Technology to explore recent work conducted to advance the manufacturing and development process for emerging therapies, particularly gene therapy.  Read our issue here: https://lnkd.in/eVMHS8mm

Precision's Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series. "Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types." Read the article here (subscription required): https://hubs.ly/Q02jhS1j0 #precisionmedicine #biopharma #clinicaltrials

#Webinar now available on demand! How to apply quality by design principles to cell and gene therapy release testing In this webinar Audrey Chang (Executive Director, WuXi Advanced Therapies) will discuss how to apply quality by design principles to cell and #genetherapy release testing and how to develop and use #QCassays. Watch this webinar to learn about: ·       Concerns surrounding adventitious agent and product characterization that must be addressed with cell and #genetherapyproducts ·       Why manufacturing and testing of cell and gene therapy products should not be regarded as a series of discrete events, but rather as a continuum of interdependent activities ·       Developing and using QC assays that can facilitate both product and process understanding and control

Precision's Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series. "Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types." Read the article here (subscription required): https://hubs.ly/Q02jkmfX0 #precisionmedicine #biopharma #clinicaltrials